Nonetheless, several gaps remain: the precise molecular mechanisms underlying METTL1’s selective regulation of specific mRNA translation are not fully elucidated; the functional heterogeneity of METTL1 across tissues and tumor types requires validation with larger clinical cohorts and multi-omics analyses; and the development of specific METTL1 inhibitors or clinically feasible interventions is still in its early stages. This evidence concerns the gene METTL1 and neoplasm.